Overview

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:
0

Participant gender:
All

Summary

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib

Criteria

Inclusion Criteria:

- Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque
psoriasis for at least 12 months; in generally good health; on stable dose of
non-prohibited medications; able to stop current psoriasis therapy (systemic or
topical) for several weeks prior to and during study participation.

Exclusion Criteria:

- Serious underlying disease including viral disorders such as hepatitis or HIV or skin
condition that would interfere with skin biopsies or evaluation of psoriasis;
conditions that could interfere with drug absorption after oral administration;
history of malignancy or auto-immune disease.

- Use of oral or injected corticosteroids (steroids).